Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Stockholm Needle and Syringe Program, Stockholm Centre for Dependency Disorders, Stockholm, Sweden.
Subst Abuse Treat Prev Policy. 2023 Apr 22;18(1):24. doi: 10.1186/s13011-023-00533-2.
Opioid overdoses are a growing concern, particularly among people who inject drugs. Sweden, with a comparatively high proportion of drug-related mortality, introduced its first Take-Home Naloxone (THN) program in 2018, at the Stockholm needle and syringe program (NSP). In this study we compare THN participant characteristics regarding refills and overdose reversals as well as investigate predictors associated with number of reversals. We also investigate interventions performed in overdose situations and endpoints for naloxone doses.
This was a prospective open inclusion cohort study conducted between January 24 2018 and March 31 2022 at the Stockholm NSP. Participants received THN, free of charge, after a training session and provided data regarding drug use and overdose experiences. During refill visits, participants reported if the naloxone was used for overdose reversal and, if so, responded to a ten-item questionnaire which included stating whether the naloxone recipient was the participant themselves or somebody else. Questionnaire data was combined with NSP database demographic data. Zero-inflated Poisson regression was applied to analyse predictors for number of reported overdose reversals.
Among study participants (n = 1,295), 66.5% stated opioids as their primary drug, and 61.4% and 81.0% had previous experience of a personal or witnessed overdose, respectively. Overall, 44.0% of participants reported a total of 1,625 overdose reversals and the victim was known to have survived in 95.6% of cases. Stimulant use (aIRR 1.26; 95% CI 1.01, 1.58), benzodiazepine use (aIRR 1.75; 95% CI 1.1, 2.78) and homelessness (aIRR 1.35; 95% CI 1.06, 1.73) were predictors associated with an increased number of reported overdose reversals. Mortality was higher among those who reported at least one overdose reversal (HR 3.4; 95% CI 2.2, 5.2).
An NSP's existent framework can be utilised to effectively implement a THN program, provide basic training and reach numerous high-risk individuals. During the four-year study, THN participants reversed a sizeable number of potentially fatal overdoses, of which many were reported by participants whose primary drug was not opioids. Naloxone refill rate was high, indicating that participants were motivated to maintain a supply of naloxone in case of future overdose events.
阿片类药物过量是一个日益严重的问题,尤其是在注射毒品的人群中。瑞典的药物相关死亡率相对较高,于 2018 年在斯德哥尔摩的针具交换项目(NSP)推出了首个纳洛酮带回家(THN)计划。在这项研究中,我们比较了 THN 参与者在续药和逆转过量方面的特征,以及调查与逆转次数相关的预测因素。我们还调查了过量情况下的干预措施和纳洛酮剂量的终点。
这是一项前瞻性开放纳入队列研究,于 2018 年 1 月 24 日至 2022 年 3 月 31 日在斯德哥尔摩的 NSP 进行。参与者在参加培训课程后免费获得 THN,并提供有关药物使用和过量经验的数据。在续药就诊时,参与者报告纳洛酮是否用于逆转过量,如果是,则回答十项问卷,包括纳洛酮的接受者是否是参与者本人或其他人。问卷数据与 NSP 数据库的人口统计学数据相结合。应用零膨胀泊松回归分析报告的过量逆转次数的预测因素。
在研究参与者(n=1295)中,66.5%表示阿片类药物是他们的主要药物,61.4%和 81.0%分别有过个人或目睹过的过量经历。总体而言,44.0%的参与者报告了总共 1625 次过量逆转,受害者在 95.6%的情况下幸存下来。兴奋剂使用(ARR 1.26;95%CI 1.01,1.58)、苯二氮䓬类药物使用(ARR 1.75;95%CI 1.1,2.78)和无家可归(ARR 1.35;95%CI 1.06,1.73)与报告的过量逆转次数增加相关。报告至少一次过量逆转的人死亡率更高(HR 3.4;95%CI 2.2,5.2)。
NSP 现有的框架可用于有效地实施 THN 计划,提供基本培训并接触到众多高危人群。在四年的研究中,THN 参与者逆转了大量潜在致命的过量,其中许多是参与者报告的,而他们的主要药物不是阿片类药物。纳洛酮续药率很高,表明参与者有动机在未来发生过量事件时维持纳洛酮供应。